Skip to main content
Article thumbnail
Location of Repository

A Large Scale shRNA Barcode Screen Identifies the Circadian Clock Component ARNTL as Putative Regulator of the p53 Tumor Suppressor Pathway

By Jasper Mullenders, Armida W. M. Fabius, Mandy Madiredjo, René Bernards and Roderick L. Beijersbergen
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2006). 39 UTR seed matches, but not overall identity, are associated with RNAi off-targets.
  2. (2007). A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
  3. (2004). A large-scale RNAi screen in human cells identifies new components of the p53 pathway.
  4. (2006). A loss-of-function RNA interference screen for molecular targets in cancer.
  5. (2006). A ubiquitin ligase complex assembles linear polyubiquitin chains.
  6. (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain.
  7. (2008). Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
  8. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas.
  9. (2006). An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
  10. (2008). Cancer proliferation gene discovery through functional genomics.
  11. (2002). Circadian rhythms from flies to human.
  12. (2003). Control mechanism of the circadian clock for timing of cell division in vivo.
  13. (2002). Coordinated transcription of key pathways in the mouse by the circadian clock.
  14. (2006). Divorcing ARF and p53: an unsettled case.
  15. (2006). Early aging and age-related pathologies in mice deficient in BMAL1, the core componentof the circadian clock.
  16. (2007). Histone deacetylase inhibitors: signalling towards p21cip1/waf1.
  17. (2003). Identification of the ubiquitin-protein ligase that recognizes oxidized IRP2.
  18. (2000). Interacting molecular loops in the mammalian circadian clock.
  19. Lane DP (2007) p53 in health and disease.
  20. (2008). Levine A
  21. (2004). Mammalian circadian biology: elucidating genome-wide levels of temporal organization.
  22. (1995). Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control.
  23. (2006). Minimizing the risk of reporting false positives in large-scale RNAi screens.
  24. (2000). Mop3 is an essential component of the master circadian pacemaker in mammals.
  25. (2001). Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3.
  26. (2005). Nuclear-cytoplasmic shuttling of a RING-IBR protein RBCK1 and its functional interaction with nuclear body proteins.
  27. (2006). p53 ubiquitination: Mdm2 and beyond.
  28. (2006). polyubiquitination and degradation of SOCS6 associated proteins.
  29. (2008). Profiling essential genes in human mammary cells by multiplex RNAi screening.
  30. (2007). RBCK1 negatively regulates tumor necrosis factor- and interleukin-1-triggered NFkappaB activation by targeting TAB2/3 for degradation.
  31. (2006). Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
  32. (2004). Regulation of p53 activity through lysine methylation.
  33. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage.
  34. (1998). Role of the CLOCK protein in the mammalian circadian mechanism.
  35. (2003). Structure-function analysis of the A20-binding inhibitor of NF-kappa
  36. (2008). The circadian clock component BMAL1 is a critical regulator of p21WAF1/ CIP1 expression and hepatocyte proliferation.
  37. (2003). The circadian clock: pacemaker and tumour suppressor.
  38. (2006). The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells.
  39. (2002). The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo.
  40. (1998). The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53.
  41. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
  42. (2003). The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene.
  43. (1999). The zinc finger protein A20 inhibits TNF-induced NF-kappaBdependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN.
  44. (2001). Time zones: a comparative genetics of circadian clocks.
  45. (2003). Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation.
  46. (1993). WAF1, a potential mediator of p53 tumor suppression.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.